Related references
Note: Only part of the references are listed.Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate Therapy
Scott T. Avecilla et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays Which Assay Is Helpful?
Joyce Curvers et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Joachim Stangier et al.
BLOOD COAGULATION & FIBRINOLYSIS (2012)
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Maarten G. Lansberg et al.
CHEST (2012)
Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Walter Ageno et al.
CHEST (2012)
Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines
Clive Kearon et al.
CHEST (2012)
Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Anne Holbrook et al.
CHEST (2012)
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial
Jeff S. Healey et al.
CIRCULATION (2012)
Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls: Results of a Multicenter Field Trial
Meyer Michel Samama et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2012)
Renal Profiles of Anticoagulants
Sebastian Harder
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban
J. HARENBERG et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Bleeding Risk with Dabigatran in the Frail Elderly
Paul Harper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Determination of Dabigatran in Human Plasma Samples
Job Harenberg et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2012)
Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
Jonathan Douxfils et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin
Helen Mani et al.
THROMBOSIS AND HAEMOSTASIS (2012)
The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters
Laura Green et al.
THROMBOSIS RESEARCH (2012)
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories
L. M. Asmis et al.
THROMBOSIS RESEARCH (2012)
The Use of Dabigatran in Elderly Patients
Matthieu Legrand et al.
ARCHIVES OF INTERNAL MEDICINE (2011)
Laboratory assessment of new anticoagulants
Meyer M. Samama et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study
A. Tripodi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
Job Harenberg et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants
Larisa H Cavallari et al.
PHARMACOTHERAPY (2011)
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time
Helen Mani et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Tomas L. Lindahl et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement
Genevieve Freyburger et al.
THROMBOSIS RESEARCH (2011)
Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
Isla M. Ogilvie et al.
AMERICAN JOURNAL OF MEDICINE (2010)
Rivaroxaban: A New Oral Factor Xa Inhibitor
Elisabeth Perzborn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
New oral antithrombotics: a need for laboratory monitoring. For
P. Mismetti et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Assays for Measuring Rivaroxaban: Their Suitability and Limitations
Edelgard Lindhoff-Last et al.
THERAPEUTIC DRUG MONITORING (2010)
Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Comparison of monitoring methods for lepirudin: Impact of warfarin and lupus anticoagulant
Birgitta Salmela et al.
THROMBOSIS RESEARCH (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Population pharmacokinetics and pharmacodynamics of rivaroxaban - An oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2008)
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2008)
Dabigatran with or without concomitant Aspirin compared with Warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
Michael D. Ezekowitz et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Joachim Stangier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients:: a population model analysis
Karl-Heinz Liesenfeld et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium
C. Klaeffling et al.
THERAPEUTIC DRUG MONITORING (2006)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -: an oral, direct Factor Xa inhibitor
E Perzborn et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Anti-Xa and anti-IIa drugs alter International Normalized Ratio measurements: Potential problems in the monitoring of oral anticoagulants
M Tobu et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2004)
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
G Nowak
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
Ecarin chromogenic assay - A new method for quantitative determination of direct thrombin inhibitors like hirudin
U Lange et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
Share Paper
